Dear Editor,Perinephric myxoid pseudotumor of fat(PMPF)is a recently described entity with only a few cases published in the literature.On imaging,the appearances overlap with other better-known fat-containing lesions...Dear Editor,Perinephric myxoid pseudotumor of fat(PMPF)is a recently described entity with only a few cases published in the literature.On imaging,the appearances overlap with other better-known fat-containing lesions such as angiomyolipoma and retroperitoneal liposarcoma.We present a novel case of PMPF in a young male patient with horseshoe kidney.We discuss the imaging characteristics on computed tomography(CT)and magnetic resonance imaging,differential diagnoses,as well as the histopathological features of this rare entity.Consent was obtained from the patient for treatment and publication.展开更多
Background and Objective:Hong Kong,like many parts of Asia,faces a high burden of hepatocellular carcinoma(HCC)caused by high endemic rates of hepatitis B virus infection.Hong Kong clinicians have developed a high lev...Background and Objective:Hong Kong,like many parts of Asia,faces a high burden of hepatocellular carcinoma(HCC)caused by high endemic rates of hepatitis B virus infection.Hong Kong clinicians have developed a high level of expertise in HCC treatment across surgical,transarterial,ablative,radiotherapeutic and systemic modalities.This publication summarizes the latest evidence-based recommendations on how these modalities should be used.Methods:In two meetings held in 2020,a multidisciplinary panel of surgeons,oncologists and interventional radiologists performed a narrative review of evidence on the management of HCC,with an emphasis on treatment of HCC not amenable to surgical resection.Close attention was paid to new evidence published since the previous version of these statements in 2018.Key Content and Findings:The expert panel has formulated 60 consensus statements to guide the staging and treatment of unresectable HCC.Since the previous version of these statements,considerable additions have been made to the recommendations on use of targeted therapies and immunotherapies because of the large volume of new evidence.Conclusions:Our consensus statements offer guidance on how to select HCC patients for surgical or non-surgical treatment and for choosing among non-surgical modalities for patients who are not candidates for resection.In particular,there is a need for more evidence to aid physicians in the selection of second-line systemic therapies,as currently most data are limited to patients with disease progression on first-line sorafenib.展开更多
文摘Dear Editor,Perinephric myxoid pseudotumor of fat(PMPF)is a recently described entity with only a few cases published in the literature.On imaging,the appearances overlap with other better-known fat-containing lesions such as angiomyolipoma and retroperitoneal liposarcoma.We present a novel case of PMPF in a young male patient with horseshoe kidney.We discuss the imaging characteristics on computed tomography(CT)and magnetic resonance imaging,differential diagnoses,as well as the histopathological features of this rare entity.Consent was obtained from the patient for treatment and publication.
文摘Background and Objective:Hong Kong,like many parts of Asia,faces a high burden of hepatocellular carcinoma(HCC)caused by high endemic rates of hepatitis B virus infection.Hong Kong clinicians have developed a high level of expertise in HCC treatment across surgical,transarterial,ablative,radiotherapeutic and systemic modalities.This publication summarizes the latest evidence-based recommendations on how these modalities should be used.Methods:In two meetings held in 2020,a multidisciplinary panel of surgeons,oncologists and interventional radiologists performed a narrative review of evidence on the management of HCC,with an emphasis on treatment of HCC not amenable to surgical resection.Close attention was paid to new evidence published since the previous version of these statements in 2018.Key Content and Findings:The expert panel has formulated 60 consensus statements to guide the staging and treatment of unresectable HCC.Since the previous version of these statements,considerable additions have been made to the recommendations on use of targeted therapies and immunotherapies because of the large volume of new evidence.Conclusions:Our consensus statements offer guidance on how to select HCC patients for surgical or non-surgical treatment and for choosing among non-surgical modalities for patients who are not candidates for resection.In particular,there is a need for more evidence to aid physicians in the selection of second-line systemic therapies,as currently most data are limited to patients with disease progression on first-line sorafenib.
